Phenotypic, ethologically based resolution of spontaneous and D2‐like vs D1‐like agonist‐induced behavioural topography in mice with congenic D3 dopamine receptor “knockout”

Uncertainty as to the functional role of the D3 dopamine receptor, due primarily to a paucity of selective agonists or antagonists, is being addressed in mice with targeted gene deletion (“knockout”) thereof. This study describes, for the first time, the phenotype of congenic D3‐null mice. Initially, 129/Sv × C57BL/6 D3‐null mice were backcrossed 14 times onto C57BL/6; they were then assessed using an ethologically based approach which resolves all topographies of behaviour within the mouse repertoire. The ethogram of D3‐null mice, on comparison with wildtypes, was characterised by no alteration in any topography of behaviour over an initial period of exploration; subsequent assessment over several hours revealed only increased rearing among females due to delayed habituation. Low doses of the selective D2‐like agonist RU 24213 (0.016–0.25 mg/kg) inhibited topographies of exploratory behaviour; this effect was diminished in D3‐null mice only when investigated following prolonged habituation, and then only for certain topographies of behaviour, primarily sniffing and rearing. High doses of RU 24213 (0.1–12.5 mg/kg) induced stereotyped sniffing and “ponderous” locomotion, while the selective D1‐like agonist SK&F 83959 (0.016–2.0 mg/kg) promoted characteristic grooming syntax; these effects did not differ materially between the genotypes. When examined topographically on an essentially congenic C57BL/6 background (<0.005% 129/Sv), the resultant phenotype indicated essential conservation of the mouse ethogram, high‐dose D2‐like stimulatory effects, and D1‐like stimulatory effects in the absence of D3 receptors. A role for D3 receptors in inhibitory processes appeared topographically circumscribed and only when baseline levels of behaviour were low. Synapse 46:19–31, 2002. © 2002 Wiley‐Liss, Inc.

[1]  J. Waddington,et al.  Dopaminergic behaviour stereospecifically promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390 , 2004, Psychopharmacology.

[2]  J. Waddington,et al.  D1-Like Dopamine Receptors: Molecular Biology and Pharmacology , 2002 .

[3]  M. Low,et al.  Comparative, Topographically-Based Evaluation of Behavioural Phenotype and Specification of D1-Like:D2 Interactions in a Line of Incipient Congenic Mice with D2 Dopamine Receptor ‘Knockout’ , 2001, Neuropsychopharmacology.

[4]  K. Wicke,et al.  The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. , 2001, European journal of pharmacology.

[5]  J. Waddington,et al.  The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion (‘knockout’) , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  N. Koshikawa,et al.  Topographical assessment and pharmacological characterization of orofacial movements in mice: dopamine D(1)-like vs. D(2)-like receptor regulation. , 2001, European journal of pharmacology.

[7]  R. Mailman,et al.  Quantification of D1B (D5) receptors in dopamine D1A receptor‐deficient mice , 2001, Synapse.

[8]  P. Strange,et al.  Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. , 2001, Pharmacological reviews.

[9]  J. Hagan,et al.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. , 2000, The Journal of pharmacology and experimental therapeutics.

[10]  K. Berridge,et al.  Super‐stereotypy I: Enhancement of a complex movement sequence by systemic dopamine D1 agonists , 2000, Synapse.

[11]  P. Fletcher,et al.  Modification of dopamine D1 receptor knockout phenotype in mice lacking both dopamine D1 and D3 receptors , 2000 .

[12]  M. Millan,et al.  S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.

[13]  J. Waddington,et al.  Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D2 dopamine receptor , 2000, Neuropharmacology.

[14]  A. Undie,et al.  Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways , 2000, Neuropharmacology.

[15]  R. Hen,et al.  Complications associated with genetic background effects in research using knockout mice , 1999, Psychopharmacology.

[16]  C. Schmauss,et al.  Decreased c-fos Responses to Dopamine D1Receptor Agonist Stimulation in Mice Deficient for D3Receptors* , 1999, The Journal of Biological Chemistry.

[17]  R. Depoortère,et al.  Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists , 1999, Neuropharmacology.

[18]  D. Sibley,et al.  Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase , 1999, Neuroscience.

[19]  B. Everitt,et al.  Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist , 1999, Nature.

[20]  J. Brosius,et al.  Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors , 1999, Neuroscience.

[21]  J. Crabbe,et al.  Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.

[22]  R. Depoortère,et al.  Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice , 1999, Neuropharmacology.

[23]  F. J. White,et al.  Dopamine D3 receptor mutant and wild‐type mice exhibit identical responses to putative D3 receptor‐selective agonists and antagonists , 1999, Synapse.

[24]  J. Waddington,et al.  SK&F 83959 and non-cyclase-coupled dopamine D1-like receptors in jaw movements via dopamine D1-like/D2-like receptor synergism. , 1999, European journal of pharmacology.

[25]  J. C. Stoof,et al.  The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. , 1999, European journal of pharmacology.

[26]  D. Sibley,et al.  New insights into dopaminergic receptor function using antisense and genetically altered animals. , 1999, Annual review of pharmacology and toxicology.

[27]  D. Sibley,et al.  Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax , 1998, Neuropharmacology.

[28]  S. Fuchs,et al.  Human D3 dopamine receptor in the medulloblastoma TE671 cell line: cross‐talk between D1 and D3 receptors , 1998, FEBS letters.

[29]  P. Sokoloff,et al.  Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence 1 Published on the World Wide Web on 24 November 1997. 1 , 1998, Brain Research Reviews.

[30]  P. Sokoloff,et al.  Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions , 1998, The European journal of neuroscience.

[31]  M. Low,et al.  Locomotor Activity in D2 Dopamine Receptor-Deficient Mice Is Determined by Gene Dosage, Genetic Background, and Developmental Adaptations , 1998, The Journal of Neuroscience.

[32]  J. Waddington,et al.  Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach , 1998, Psychopharmacology.

[33]  F. J. White,et al.  Alterations in Dopamine Release But Not Dopamine Autoreceptor Function in Dopamine D3 Receptor Mutant Mice , 1998, The Journal of Neuroscience.

[34]  D. Sibley,et al.  Behavioral analysis of multiple D1-like dopamine receptor subtypes: new agents and studies in transgenic mice with D1A receptor knockout. , 1998, Advances in pharmacology.

[35]  S. R. Nash,et al.  Dopamine receptors: from structure to function. , 1998, Physiological reviews.

[36]  H. Steiner,et al.  D3 Dopamine Receptor-Deficient Mouse: Evidence for Reduced Anxiety , 1997, Physiology & Behavior.

[37]  S. Tonegawa,et al.  Dopamine D3 Receptor Mutant Mice Exhibit Increased Behavioral Sensitivity to Concurrent Stimulation of D1 and D2 Receptors , 1997, Neuron.

[38]  B. Levant The D3 dopamine receptor: neurobiology and potential clinical relevance. , 1997, Pharmacological reviews.

[39]  P. Calabresi,et al.  Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. , 1997, Neuroscience.

[40]  Allan Collins,et al.  Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies , 1997, Psychopharmacology.

[41]  R. Gerlai Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? , 1996, Trends in Neurosciences.

[42]  C. Gerfen,et al.  A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Waddington,et al.  Pharmacological characterization of behavioural responses to SK&F 83959 in relation to ‘D1‐like’ dopamine receptors not linked to adenylyl cyclase , 1995, British journal of pharmacology.

[44]  S. A. Daly,et al.  Behavioural pharmacology op ‘D-1-like’ dopamine receptors: Further subtyping, new pharmacological probes and interactions with ‘D-2-like’ receptors , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[45]  C. Marsden,et al.  Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour. , 1995, Biochemical pharmacology.

[46]  H. Sarau,et al.  Evidence for a Distinct D1Like Dopamine Receptor that Couples to Activation of Phosphoinositide Metabolism in Brain , 1994, Journal of neurochemistry.

[47]  C. Sánchez,et al.  Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. , 1992, European journal of pharmacology.

[48]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[49]  D. Sibley,et al.  Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilization in Xenopus oocytes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  F. Labrie,et al.  Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels , 1980, Neuropharmacology.